UCB Acquires Candid Therapeutics 

UCB has announced that it entered into an agreement to acquire Candid Therapeutics. Under the terms of the agreement, UCB will pay $2 billion upfront payments and up to $200 million in potential future milestone payments.  In March, it was reported that Candid was to...